Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma

Open access
Jiang, Yan-Yi, Lin, De-Chen, Mayakonda, Anand, Hazawa, Masaharu, Ding, Ling-Wen, Chien, Wen-Wen, Xu, Liang, Chen, Ye, Xiao, Jin-Fen, Senapedis, William, Baloglu, Erkan, Kanojia, Deepika, Shang, Li, Xu, Xin, Yang, Henry, Tyner, Jeffrey W, Wang, Ming-Rong, Koeffler, H Phillip · 2017 · Gut

Abstract

Objectives: Oesophageal squamous cell carcinoma (OSCC) is an aggressive malignancy and the major histological subtype of oesophageal cancer. Although recent large-scale genomic analysis has improved the description of the genetic abnormalities of OSCC, few targetable genomic lesions have been identified, and no molecular therapy is available. This study aims to identify druggable candidates in this tumour. Design: High-throughput small-molecule inhibitor screening was performed to identify potent anti-OSCC compounds. Whole-transcriptome sequencing (RNA-Seq) and chromatin immunoprecipitation sequencing (ChIP-Seq) were conducted to decipher the mechanisms of action of CDK7 inhibition in OSCC. A variety of in vitro and in vivo cellular assays were performed to determine the effects of candidate genes on OSCC malignant phenotypes. Results: The unbiased high-throughput small-molecule inhibitor screening led us to discover a highly potent anti-OSCC compound, THZ1, a specific CDK7 inhibitor. RNA-Seq revealed that low-dose THZ1 treatment caused selective inhibition of a number of oncogenic transcripts. Notably, further characterisation of the genomic features of these THZ1-sensitive transcripts demonstrated that they were frequently associated with super-enhancer (SE). Moreover, SE analysis alone uncovered many OSCC lineage-specific master regulators. Finally, integrative analysis of both THZ1-sensitive and SE-associated transcripts identified a number of novel OSCC oncogenes, including PAK4, RUNX1, DNAJB1, SREBF2 and YAP1, with PAK4 being a potential druggable kinase. Conclusions: Our integrative approaches led to a catalogue of SE-associated master regulators and oncogenic transcripts, which may significantly promote both the understanding of OSCC biology and the development of more innovative therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2016-311818

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 212

Metadata

Authors
Jiang, Y.-Y., Lin, D.-C., Mayakonda, A., Hazawa, M., Ding, L.-W., Chien, W.-W., Xu, L., Chen, Y., Xiao, J.-F., Senapedis, W., Baloglu, E., Kanojia, D., Shang, L., Xu, X., Yang, H., Tyner, J. W., Wang, M.-R., & Koeffler, H. P.
Venue
Gut
Publisher
BMJ
Published
2016-05-10
Volume
66
Issue
8
Pages
1358-1368
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2383217883
Cited by
212
References
4
FWCI
18.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. https://app.cochat.ai/papers/10.1136/gutjnl-2016-311818
The paper
Jiang, Y.-Y., Lin, D.-C., Mayakonda, A., Hazawa, M., Ding, L.-W., Chien, W.-W., Xu, L., Chen, Y., Xiao, J.-F., Senapedis, W., Baloglu, E., Kanojia, D., Shang, L., Xu, X., Yang, H., Tyner, J. W., Wang, M.-R., & Koeffler, H. P. (2017). Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut. https://doi.org/10.1136/gutjnl-2016-311818

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.